成人特发性肺纤维化(更新)与进展性肺纤维化:ATS/ERS/JRS/ALAT临床实践指南
该指南由ATS、ERS、JRS和ALAT联合更新,针对成人特发性肺纤维化(IPF)及非IPF间质性肺疾病(ILD)中进展性肺纤维化(PPF)。通过共识更新IPF的影像和病理标准,并基于GRADE方法对经支气管冷冻肺活检、基因组分类检测、抗酸药物及抗反流手术提出推荐;对PPF进行定义并制定影像和生理标准,基于系统评价对吡非尼酮和尼达尼布提出推荐。
要点
- 经支气管冷冻肺活检在具备专业技术的中心可作为外科肺活检的替代选择(有条件推荐)。
- 不推荐抗酸药物或抗反流手术治疗IPF(有条件推荐);基因组分类检测无推荐。
- PPF定义为过去一年内出现三项标准中至少两项(症状恶化、影像进展、生理进展)且无其他解释。
核心结论
- 指南对IPF更新及PPF管理提出有条件推荐,旨在为临床医生提供合理决策依据。
研究设计与样本
- 由多学科ILD专家、方法学家和患者代表组成的委员会制定,采用系统评价和GRADE方法形成推荐。
主要发现
- IPF更新:经支气管冷冻肺活检可作为外科肺活检的替代(有条件推荐);不推荐抗酸药物和抗反流手术(有条件推荐);基因组分类检测无推荐。
- PPF:定义为过去一年内至少两项标准(症状恶化、影像进展、生理进展)且无其他解释;推荐尼达尼布(有条件推荐),并建议进一步研究吡非尼酮。
关键数值与推荐
- PPF定义:在非IPF的ILD患者中,过去一年内出现三项标准中至少两项(症状恶化、影像进展、生理进展)且无其他解释。
临床怎么用
- 在具备专业技术的中心,可考虑经支气管冷冻肺活检替代外科肺活检。
- 对非IPF的ILD患者,若符合PPF定义,可考虑使用尼达尼布。
- 不推荐使用抗酸药物或抗反流手术治疗IPF。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results:1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians.
引用
- Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022. PMID: 35486072. doi:10.1164/rccm.202202-0399ST
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。